Eduardo Michelen-Gómez

University of Puerto Rico System

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Karina J. Cancel-Artau

University of Puerto Rico System

Francisco Colón-Fontánez

University of Puerto Rico, Medical Sciences Campus

Rafael F. Martín‐García

University of Puerto Rico System

Amara Guerrero

Central University of the Caribbean

Gabriel Guardiola-Dávila

Central University of the Caribbean

Rocío Cardona

University of Puerto Rico, Medical Sciences Campus

Deyson Lorenzo‐Ríos

University of Puerto Rico System

Xavier Sánchez‐Flores

University of Puerto Rico System

Natalio Izquierdo

University of Puerto Rico, Medical Sciences Campus

Gabriel E Arias-Berrios

University of Puerto Rico System

Cooperative Institutions

University of Puerto Rico System

University of Puerto Rico, Medical Sciences Campus

Central University of the Caribbean

Marqués de Valdecilla University Hospital

Washington University in St. Louis

Ponce Health Sciences University

Christie's

University of Southern California

Texas Tech University

Medical College of Wisconsin

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Clinical Consequences of Delayed Treatment for Tinea Capitis (Ringworm of the Scalp): A Case Report.

PubMed (2024)

Victor J Raimundi-Santos Eduardo Michelen-Gómez Karina J. Cancel-Artau Francisco Colón-Fontánez

A 6-year-old Hispanic patient presented with a 1-month history of pruritic patches on her scalp, characterized by hair loss, black dots, and dandruff-like scales. The patient was seen by her primary care physician, who prescribed ketoconazole 2% shampoo. This provided little relief for her symptoms, which prompted her admission to nearby hospital, where fluconazole was administered intravenously and mometasone lotion applied. The patient was discharged and instructed to use the ketoconazole shampoo and mometasone lotion. The previously prescribed medications failed to improve her now enlarged, inflamed, scaly, pustule-speckled lesions. Given her condition, she was admitted to the University Pediatric Hospital in San Juan, where the Dermatology Department was consulted. Cultures were taken from the lesions, revealing the presence of Trichophyton tonsurans, which led to the diagnosis of tinea capitis (ringworm of the scalp) with kerion formation. In addition, multiple nits and adult lice characteristic of Pediculus humanus capitis were observed. A 6-week course of griseofulvin, a 1-week course of permethrin solution, and a 5-day course of oral prednisolone were started, effectively cleared the patient's inflammation and fungal infection. This case highlights how there exist areas of improvement in terms of interprofessional communication between physicians, as well a need to increase awareness of the proper treatment for this common pediatric skin condition. We postulate that in doing so, similar cases could be spared the unfortunate results of untreated tinea capitis, that is, kerion formation and the possible scarring this lesion can produce.

Tinea Capitis

Source

Cite

Citations (0)

Age-specific changes in genome-wide methylation enrich for Foxa2 and estrogen receptor alpha binding sites

PLoS ONE (2018)

Nishanth Uli Eduardo Michelen-Gómez Enrique Ramos Todd E. Druley

The role of DNA methylation patterns in complex phenotypes remains unclear. To explore this question, we adapted our methods for rare variant analysis to characterize genome-wide murine DNA hybridization array to investigate methylation at CpG islands, shores, and regulatory elements. We have applied this platform to compare age and tissue- specific methylation differences in the brain and spleen of young and aged mice. As expected from prior studies, there are clear global differences in organ-specific, but not age-specific, methylation due mostly to changes at repetitive elements. Surprisingly, out of 200,000 loci there were only 946 differentially methylated cytosines (DMCs) between young and old samples (529 hypermethylated, 417 hypomethylated in aged mice) compared to thousands of tissue-specific DMCs. Hypermethylated loci were clustered around the promoter region of Sfi1, exon 2 of Slc11a2, Drg1, Esr1 and Foxa2 transcription factor binding sites. In particular, there were 75 hypermethylated Foxa2 binding sites across a 2.7 Mb region of chromosome 11. Hypomethylated loci were clustered around Mid1, Isoc2b and genome-wide loci with binding sites for Foxa2 and Esr1, which are known to play important roles in development and aging. These data suggest discreet tissue-independent methylation changes associated with aging processes such as cell division (Sfi1, Mid1), energy production (Drg1, Isoc2b) and cell death (Foxa2, Esr1).

FOXA2

Estrogen receptor alpha

CpG site

Differentially methylated regions

DNA binding site

10.1371/journal.pone.0203147

Cite

Citations (5)

Failure of Biologic Therapy in Psoriasis.

Puerto Rico health sciences journal (2021)

Rocío Cardona Natalia Pelet del Toro Eduardo Michelen-Gómez Gabriel E Arias-Berrios Rafael F. Martín‐García

Objective: This study aims to describe the frequency of biologic therapy failure in psoriasis patients along with associated patient demographics and characteristics. Methods: This was a retrospective medical-record review of psoriasis patients evaluated from January 1st, 2013, through May 1st, 2018, and who failed at least once to adhere to their biologic therapy. Results: Seventy-seven patients with psoriasis who had discontinued biologic therapy at least once were included in this study. Hypertension (58.4%), diabetes (37.7%), dyslipidemia (27.3%), and psoriatic arthritis (23.4%) were the main comorbidities observed. Adalimumab (ADA, 80.5%), ustekinumab (UST, 70.1%), and etanercept (ETA, 14.2%) were the most frequently used biologics in our cohort. The biologic with the longest mean duration of use prior to its discontinuation was UST (17.0 months), followed by ADA (15.9 months) and ETA (13.6 months). Conclusion: The most common reason for discontinuing biologic therapy was that said therapy was not effective, though for ETA and UST, the fact that biologic therapies are not universally covered by insurance company was found to be associated with their discontinuation, as well. There were no statistically significant associations found between biologic therapy discontinuation and age, gender, or comorbidities, which last included obesity, class I. Larger studies are warranted to identify risk factors associated with biologic therapy failure to help guide drug selection, decrease morbidity associated with such nonadherence and improve patient outcomes.

Ustekinumab

Discontinuation

Golimumab

Dyslipidemia

Source

Cite

Citations (1)

Compound Heterozygous Mutations in the BBS-1 Gene and its Clinical Presentation: A Case Report.

PubMed (2021)

Eduardo Michelen-Gómez Gabriel Guardiola-Dávila Natalio Izquierdo

Compound heterozygous mutations, where two distinct mutated alleles are present within a particular gene, can give rise to the Bardet-Biedl syndrome (BBS). There is limited evidence suggesting that some compound heterozygotes can present with milder phenotypic characteristics than homozygotes. We report on the clinical characteristics of a 22-year-old Puerto Rican male who was compound heterozygous for the Bardet-Biedl syndrome type 1. Our patient had deteriorating visual acuity since early childhood. Clinical and ophthalmic examination revealed retinal dystrophy, polydactyly, and very mild learning disabilities. No additional systemic complications commonly observed in patients with the BBS were present. Allele-specific testing and DNA sequencing revealed compound heterozygous mutations (M390R and E549X) in the BBS1 gene. Our findings could suggest that patients who are compound heterozygotes for these specific BBS mutations can exhibit milder clinical signs than homozygous patients.

Compound heterozygosity

Bardet–Biedl Syndrome

Heterozygote advantage

Polydactyly

Source

Cite

Citations (0)

54375 Melasma Flaring and Unmasking by 1,927-nm Nonablative Fractional Laser Therapy

Journal of the American Academy of Dermatology (2024)

Karina J. Cancel-Artau Eduardo Michelen-Gómez Amara Guerrero Claudia Pérez‐Martínez Cristina Javier-Brau

Melasma

10.1016/j.jaad.2024.07.257

Cite

Citations (0)

Seizures of unknown etiology associated with brittle hair: A diagnostic challenge

JAAD Case Reports (2021)

Marely Santiago-Vázquez Eduardo Michelen-Gómez Alvaro J. Ramos J. Eduardo Morales Barrera Marisel Vázquez Correa

Menkes disease (MD) is a rare X-linked recessive disorder caused by defective copper metabolism, which is associated with inactivating mutations in the ATP7A gene. It has an estimated incidence of 1 in 35,000 live births.1-3 Clinical manifestations usually begin during early infancy and include progressive neurodegeneration, connective tissue disturbances, failure to thrive, intractable seizures, and kinky, brittle hair. Children who develop MD tend to suffer from progressive neurologic deterioration and are likely to die before they reach 3 years of age.

Etiology

10.1016/j.jdcr.2021.10.003

Cite

Citations (0)

Compound Heterozygous Mutations in the BBS-1 Gene and its Clinical Presentation: A Case Report.

Puerto Rico health sciences journal (2021)

Eduardo Michelen-Gómez Gabriel Guardiola-Dávila Natalio Izquierdo

Compound heterozygosity

Bardet–Biedl Syndrome

Heterozygote advantage

Polydactyly

Source

Cite

Citations (0)

Failure of Biologic Therapy in Psoriasis.

PubMed (2021)

Rocío Cardona Natalia Pelet del Toro Eduardo Michelen-Gómez Gabriel E Arias-Berrios Rafael F. Martín‐García

This study aims to describe the frequency of biologic therapy failure in psoriasis patients along with associated patient demographics and characteristics.This was a retrospective medical-record review of psoriasis patients evaluated from January 1st, 2013, through May 1st, 2018, and who failed at least once to adhere to their biologic therapy.Seventy-seven patients with psoriasis who had discontinued biologic therapy at least once were included in this study. Hypertension (58.4%), diabetes (37.7%), dyslipidemia (27.3%), and psoriatic arthritis (23.4%) were the main comorbidities observed. Adalimumab (ADA, 80.5%), ustekinumab (UST, 70.1%), and etanercept (ETA, 14.2%) were the most frequently used biologics in our cohort. The biologic with the longest mean duration of use prior to its discontinuation was UST (17.0 months), followed by ADA (15.9 months) and ETA (13.6 months).The most common reason for discontinuing biologic therapy was that said therapy was not effective, though for ETA and UST, the fact that biologic therapies are not universally covered by insurance company was found to be associated with their discontinuation, as well. There were no statistically significant associations found between biologic therapy discontinuation and age, gender, or comorbidities, which last included obesity, class I. Larger studies are warranted to identify risk factors associated with biologic therapy failure to help guide drug selection, decrease morbidity associated with such nonadherence and improve patient outcomes.

Ustekinumab

Discontinuation

Golimumab

Dyslipidemia

Source

Cite

Citations (5)

52405 Biologic Therapy for Psoriasis and Risk of Malignancy- A Single-Center Retrospective Cohort Study

Journal of the American Academy of Dermatology (2024)

Eduardo Michelen-Gómez Karina J. Cancel-Artau Amara Guerrero Claudia B. Perez Valerie S Encarnación-Cortés

Single Center

Center (category theory)